抗疟药物市场－全球产业规模、份额、趋势、机会及预测（按药物类型、疟疾类型、地区和竞争情况划分，2020-2030 年）

2024 年全球抗疟药物市场价值为 5.542 亿美元，预计到 2030 年将达到 7.1104 亿美元，复合年增长率为 4.44%。由于疟疾在撒哈拉以南非洲和亚洲部分地区等地区依然普遍存在，对有效治疗的需求依然强劲。青蒿素类联合疗法 (ACT) 凭藉其疗效及其在标准治疗方案中的既定作用继续引领市场。为因应抗药性疟疾菌株的增加，研发投入不断增加，进一步推动了市场发展。人们正在推行三重疗法、长效注射剂和儿童改良製剂等创新，以提高疗效和依从性。虽然不断取得进展，但市场面临着不断变化的抗药性模式带来的持续挑战，凸显了持续开发新型治疗方法的必要性。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

药品供应不一致

主要市场趋势

更注重草药和植物疗法

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球抗疟药物市场的影响

第五章：全球抗疟药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类型（奎宁、氯奎、氯胍、阿莫地喹、甲氟喹、羟氯奎、乙胺嘧啶等）
  • 依疟疾类型（恶性疟原虫、三日疟原虫、间日疟原虫、卵形疟原虫、诺氏疟原虫）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美抗疟疾药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲抗疟疾药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太抗疟药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美抗疟药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲抗疟药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球抗疟药物市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Cipla Ltd
• GlaxoSmithKline Plc
• Ipca Laboratories Ltd.
• Merck & Co., Inc
• Novartis AG
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Strides Pharma Science Limited
• Glenmark Pharmaceuticals Ltd.
• Lincoln Pharmaceuticals Ltd.

第 17 章：策略建议

第18章调查会社について・免责事项

The Global Antimalarial Drugs Market was valued at USD 554.20 million in 2024 and is projected to reach USD 711.04 million by 2030, growing at a CAGR of 4.44%. With malaria remaining prevalent in regions like sub-Saharan Africa and parts of Asia, demand for effective treatments remains robust. Artemisinin-based combination therapies (ACTs) continue to lead the market due to their efficacy and established role in standard treatment protocols. The market is being further driven by increased investment in research and development aimed at addressing the rise in drug-resistant malaria strains. Innovations such as triple combination therapies, long-acting injectables, and improved formulations for children are being pursued to enhance effectiveness and adherence. While advancements continue, the market faces persistent challenges from evolving resistance patterns, highlighting the need for ongoing development of novel treatment approaches.

Key Market Drivers

Growth in Healthcare Industry

The sustained expansion of the global healthcare industry-projected to surpass USD 4 trillion annually-is significantly bolstering the antimalarial drugs market. Pharmaceuticals and biotechnology contribute nearly USD 850 billion, supported by diagnostics and medical technology. In malaria-endemic regions such as Africa, Asia, and Latin America, increased public and private investment in healthcare infrastructure has enhanced access to diagnostics and treatments. This improved accessibility enables timely intervention, allowing for broader administration of antimalarial drugs and supporting continuous market growth.

Key Market Challenges

Inconsistency in Drug Supply

Supply inconsistency remains a major hurdle in the global antimalarial drugs market, especially in regions where malaria is most prevalent. Despite advancements in drug development and distribution frameworks, many affected areas still experience irregular access to essential medications. This issue is most acute in remote or low-income regions with fragile healthcare infrastructure. Key contributing factors include limited manufacturing capacity, inefficient procurement systems, and logistical obstacles that lead to delayed or insufficient supply. Seasonal fluctuations in malaria cases-often linked to monsoon or rainy seasons-further strain these underprepared supply chains. Inadequate inventory control and fragmented distribution networks can result in stockouts at critical points of care, ultimately disrupting treatment and increasing health risks.

Key Market Trends

Increased Focus on Herbal and Plant-Based Therapies

There is a growing trend toward the development and adoption of herbal and plant-based therapies in the antimalarial drugs market. Plant-derived compounds such as quinine, quinidine, and artemisinin remain pivotal in the fight against malaria. This shift is largely influenced by rising interest in natural and traditional treatments, particularly in regions where indigenous medicine is widely practiced. Concerns regarding side effects of synthetic drugs and the emergence of resistant malaria strains have prompted researchers and pharmaceutical firms to explore botanical alternatives. Artemisinin-extracted from sweet wormwood-serves as a cornerstone of ACTs and exemplifies the clinical success of plant-based remedies. Ongoing exploration of other medicinal plants, including neem and cinchona bark, continues to expand the pipeline of potential antimalarial agents derived from natural sources.

Key Market Players

• Cipla Ltd
• GlaxoSmithKline Plc
• Ipca Laboratories Ltd.
• Merck & Co., Inc
• Novartis AG
• Zydus Cadila
• Sun Pharmaceutical Industries Ltd.
• Strides Pharma Science Limited
• Glenmark Pharmaceuticals Ltd.
• Lincoln Pharmaceuticals Ltd.

Report Scope

In this report, the Global Antimalarial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimalarial Drugs Market, By Drug Type:

• Quinine
• Chloroquine
• Proguanil
• Amodiaquine
• Mefloquine
• Hydroxychloroquine
• Pyrimethamine
• Others

Antimalarial Drugs Market, By Malaria Type:

• Plasmodium Falciparum
• Plasmodium Malariae
• Plasmodium Vivax
• Plasmodium Ovale
• Plasmodium Knowlesi

Antimalarial Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimalarial Drugs Market.

Available Customizations

Global Antimalarial Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Antimalarial Drugs Market

5. Global Antimalarial Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others)
  • 5.2.2. By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Antimalarial Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Malaria Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antimalarial Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Malaria Type
  • 6.3.2. Mexico Antimalarial Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Malaria Type
  • 6.3.3. Canada Antimalarial Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Malaria Type

7. Europe Antimalarial Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Malaria Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Antimalarial Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Malaria Type
  • 7.3.2. Germany Antimalarial Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Malaria Type
  • 7.3.3. United Kingdom Antimalarial Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Malaria Type
  • 7.3.4. Italy Antimalarial Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Malaria Type
  • 7.3.5. Spain Antimalarial Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Malaria Type

8. Asia Pacific Antimalarial Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Malaria Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antimalarial Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Malaria Type
  • 8.3.2. India Antimalarial Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Malaria Type
  • 8.3.3. South Korea Antimalarial Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Malaria Type
  • 8.3.4. Japan Antimalarial Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Malaria Type
  • 8.3.5. Australia Antimalarial Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Malaria Type

9. South America Antimalarial Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Malaria Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Antimalarial Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Malaria Type
  • 9.3.2. Argentina Antimalarial Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Malaria Type
  • 9.3.3. Colombia Antimalarial Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Malaria Type

10. Middle East and Africa Antimalarial Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Malaria Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Antimalarial Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Malaria Type
  • 10.3.2. Saudi Arabia Antimalarial Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Malaria Type
  • 10.3.3. UAE Antimalarial Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Malaria Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Antimalarial Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Cipla Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. GlaxoSmithKline Plc
• 16.3. Ipca Laboratories Ltd.
• 16.4. Merck & Co., Inc
• 16.5. Novartis AG
• 16.6. Zydus Cadila
• 16.7. Sun Pharmaceutical Industries Ltd.
• 16.8. Strides Pharma Science Limited
• 16.9. Glenmark Pharmaceuticals Ltd.
• 16.10. Lincoln Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer